摘要
Implantable Bioelectronic Systems for Early Detection of Kidney Transplant Rejection Madhvapathy SR, Wang JJ, Wang H, et al. Science. 2023;381(6662):1105–1112. Early detection of transplant rejection is key for timely diagnosis and treatment to prevent functional deterioration of graft loss. Existing noninvasive biomarkers, derived from blood or urine, are limited by suboptimal sensitivity and specificity and may only detect rejection when significant graft injury has already occurred.1 Madhvapathy et al introduced a fully implantable, wireless, bioelectronic device that can provide real-time, continuous, long-term monitoring for kidney allograft injury in a rat kidney transplant model.2 The device, implanted on the surface of kidneys, measures local organ temperature and thermal conductivity and appears to be unaffected by changes in the ambient temperature. By comparing native, isogenic transplanted and allogenic transplanted kidneys, the authors demonstrated that changes in local organ temperature, such as a characteristic transient rise and fall of temperature and a greater within-day temperature variation, correlated with histological evidence of rejection. Importantly, these changes can precede elevations in serum creatinine and urea by up to 3 wk when immunosuppression was withdrawn. An intriguing aspect to consider in the future will be how these within-day temperature variations may reflect the circadian rhythms of the immune system and the cycles of immune activation, tissue injury, and tissue repair.3 Although further research is needed before the device can be translated for human use, this study establishes that monitoring local organ temperature could be a promising surrogate for indicators of organ perfusion and inflammation. The potential of a device that can monitor for local organ immune injury continuously in real time is a significant step forward, with possible applications for both transplant and nontransplant settings. The device may also provide an early warning of poor compliance with immunosuppression, subclinical rejection, and other conditions that impact organ blood flow, such as hypovolemia. Nevertheless, key questions remain, such as the efficacy of device in detecting borderline or chronic rejection, as well as its ability to differentiate between rejection and other inflammatory processes like infection.4 Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial Limaye AP, Budde K, Humar A, et al. JAMA. 2023;330(1):33–42. Cytomegalovirus (CMV) infection remains an important cause of morbidity and mortality in solid organ transplant recipients.1 Valganciclovir, the current standard of care for prophylaxis against CMV infection, is effective but associated with toxicity, most notably myelosuppression requiring drug interruption or discontinuation. Letermovir, a CMV DNA terminase complex inhibitor, has been shown to be safe and effective for CMV prophylaxis in adult CMV-seropositive allogenic hematopoietic stem cell transplant recipients.2 However, its use in high-risk, CMV-seronegative solid organ transplant recipients is unproven. In this international, multicenter, double-masked, double-dummy, noninferiority, phase III, randomized controlled trial, 601 high-risk kidney transplant recipients, defined as CMV-seronegative patients who received a kidney from a CMV-seropositive donor, were randomized to receive oral letermovir or oral valganciclovir for up to 200 d and followed up for 52 wk.3 Letermovir was found to be noninferior to valganciclovir for the prevention of CMV disease, as assessed by an external independent masked clinical adjudication committee, with lower rates of leukopenia and neutropenia. Similarly, there were no differences in the rates of investigator-reported CMV disease and CMV DNAaemia. Importantly, none of the participants in the letermovir arm developed CMV disease within the period of prophylaxis, compared with 5 participants in the valganciclovir arm, including 3 who developed CMV DNAaemia while receiving prophylaxis and 2 who developed CMV disease after early discontinuation of prophylaxis. No known letermovir resistance-associated substitutions in viral terminase proteins (pUL51, pUL56, or pUL89) were found in the letermovir group, whereas 12.1% of participants in the valganciclovir group were found to have valganciclovir resistance-associated substitutions in the viral kinase protein (pUL97) and/or the viral DNA polymerase protein (pUL54). Other clinical events, such as rejection, graft loss, and mortality, were too infrequent to be compared meaningfully. The study clearly supports the use of letermovir for prophylaxis against CMV disease in high-risk kidney transplant recipients, although longer-term outcomes and cost-effectiveness remain unclear. Importantly, the study demonstrated lower rates of leukopenia and neutropenia when compared with valganciclovir, as well as no evidence of drug resistance. With the advent of CMV prophylaxis strategies guided by CMV-specific cell immunity assays, further research will be needed to clarify the optimal strategy to prevent CMV infection.4,5